Heart rhythm monitoring to find atrial fibrillation in adults with raised NT-proBNP
Tests 7 days of heart rhythm monitoring in adults with raised NT-proBNP.
Plain-language title generated from the registry record
Registry title: Population-based Atrial Fibrillation Screening in Individuals With NT-proBNP Above Median in the Tromsø Study
Key facts
- Where
- Tromsø, NorwaySee the 2 sites
Where in Norway
- Uit The Arctic University of NorwayTromsø, NorwayTaking people
- University Hospital of North Norway Health TrustTromsø, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital of North Norway
- Trial code
- NCT07343895
- Record updated
- 15 January 2026
- Original description
The aim is to investigate whether screening with long-term ECG monitoring in individuals with elevated NT-proBNP leads to a lower incidence of ischeamic stroke and death from vascular causes. The project is a sub-study within the 8th wave of the population based Tromsø Study. Information on previous diseases, medication use, and risk factors is collected through questionnaires, blood samples, and measurements of height, weight, blood pressure, and ECG.Read full original descriptionShow less
Atrial Fibrillation and Long Term ECG Monitoring of Heart Rhythm in the Tromsø Study
The aim is to investigate whether screening with long-term ECG monitoring in individuals with elevated NT-proBNP leads to a lower incidence of ischeamic stroke and death from vascular causes. The project is a sub-study within the 8th wave of the population based Tromsø Study. Information on previous diseases, medication use, and risk factors is collected through questionnaires, blood samples, and measurements of height, weight, blood pressure, and ECG.
A total of 4,000 individuals with NT-proBNP levels above the median, without previously known atrial fibrillation (AF) or ongoing anticoagulation therapy, will be randomized to either long-term heart rhythm monitoring (7 days) or a control group without long-term ECG monitoring (2,000 in each group). Individuals with AF in the intervention group will be offered anticoagulation therapy in accordance with current guidelines.
The intervention group and the control group will be compared with regards to incident stroke and death within a 6-year follow-up period. Information on endpoints and anticoagulation use will be obtained through linkage to national registries.
Inclusion: Age ≥40 years; NT-proBNP> median level; Informed consent for participation.
Exclusion: Use of anticoagulation therapy; History of AF (self-reported); Pacemaker/CRT device; No available smart phone.